Cayuga Biotech Inc.

Cayuga Biotech, Inc. is a US-based company focused on developing innovative therapeutic solutions aimed at addressing hemorrhage, utilizing the body's natural clotting mechanisms to enhance hemostatic responses in critical medical situations. Founded in 2015 and headquartered in New York, US, Cayuga Biotech specializes in therapeutic solutions for hemorrhage control. The company was established by Damien Kudela and Kyle Ploense.

On December 11, 2025, Cayuga Biotech raised USD 5. 000 mn in a SEED funding round led by Wharton Alumni Angels, contributing to a total amount raised of USD 5. 000 mn through 5 total deals. Cayuga Biotech specializes in innovative therapeutic solutions aimed at addressing hemorrhage, leveraging the body's natural mechanisms for blood clotting.

The company's core offerings focus on first-in-class therapeutics designed to enhance hemostatic response, providing critical support in emergency medical situations, battlefield trauma, and surgical applications. These products are intended for use by healthcare professionals, including trauma surgeons and emergency medical technicians, who require effective hemorrhage control solutions in both civilian and military settings. Cayuga Biotech's proprietary science targets significant unmet medical needs, enabling the company to operate in diverse geographical markets including North America, Europe, and select regions in Asia. The products are developed with a clear focus on improving patient outcomes in acute care environments, thereby fostering partnerships with hospitals, trauma centers, and government health agencies.

Cayuga Biotech generates revenue through a business model that includes partnerships with healthcare institutions and direct sales to hospitals and medical facilities. The transaction structure revolves around supplying their flagship therapeutics, with pricing schemes established based on the volume of product sold and specific client agreements. Typically, transactions may involve direct sales contracts or collaborative agreements for clinical trials and product launches, where hospitals and medical providers acquire these specialized therapies for their emergency response teams. The company emphasizes the importance of these partnerships in scaling its operations and enhancing distribution capabilities, thereby creating a sustainable revenue stream through consistent product utilization in critical care settings.

Additionally, strategic collaborations with research institutions and participation in clinical studies further support revenue generation and market penetration. Cayuga Biotech plans to utilize the recent funding of USD 3 million, part of a larger USD 8 million in seed and grant funding raised in December 2025, to advance the Phase 1 clinical trial for its product CAY001. The company is focused on expanding its market presence, with specific plans to launch new products and penetrate additional geographic regions by 2026. This strategy includes development initiatives aimed at enhancing their therapeutic offerings and establishing partnerships in new markets.